<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>144</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0001753224</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <issuerInfo>
      <issuerCik>0001722964</issuerCik>
      <issuerName>Y-mAbs Therapeutics, Inc.</issuerName>
      <secFileNumber>001-38650</secFileNumber>
      <issuerAddress>
        <com:street1>202 CARNEGIE CENTER</com:street1>
        <com:street2>SUITE 301</com:street2>
        <com:city>PRINCETON</com:city>
        <com:stateOrCountry>NJ</com:stateOrCountry>
        <com:zipCode>08540</com:zipCode>
      </issuerAddress>
      <issuerContactPhone>646-885-8505</issuerContactPhone>
      <nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>Gad Thomas</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
      <relationshipsToIssuer>
        <relationshipToIssuer>Officer</relationshipToIssuer>
        <relationshipToIssuer>Director</relationshipToIssuer>
      </relationshipsToIssuer>
    </issuerInfo>
    <securitiesInformation>
      <securitiesClassTitle>Common Stock</securitiesClassTitle>
      <brokerOrMarketmakerDetails>
        <name>Merrill Lynch</name>
        <address>
          <com:street1>225 Liberty St</com:street1>
          <com:street2>Floor 37</com:street2>
          <com:city>New York</com:city>
          <com:stateOrCountry>NY</com:stateOrCountry>
          <com:zipCode>10281</com:zipCode>
        </address>
      </brokerOrMarketmakerDetails>
      <noOfUnitsSold>10810</noOfUnitsSold>
      <aggregateMarketValue>56546.86</aggregateMarketValue>
      <noOfUnitsOutstanding>45218177</noOfUnitsOutstanding>
      <approxSaleDate>03/07/2025</approxSaleDate>
      <securitiesExchangeName>NASDAQ</securitiesExchangeName>
    </securitiesInformation>
    <securitiesToBeSold>
      <securitiesClassTitle>Common Stock</securitiesClassTitle>
      <acquiredDate>01/17/2025</acquiredDate>
      <natureOfAcquisitionTransaction>Vesting of restricted stock unit award</natureOfAcquisitionTransaction>
      <nameOfPersonfromWhomAcquired>Y-mAbs Therapeutics, Inc.</nameOfPersonfromWhomAcquired>
      <isGiftTransaction>N</isGiftTransaction>
      <amountOfSecuritiesAcquired>6993</amountOfSecuritiesAcquired>
      <paymentDate>01/17/2025</paymentDate>
      <natureOfPayment>Granted as part of issuer equity compensation plan</natureOfPayment>
    </securitiesToBeSold>
    <securitiesToBeSold>
      <securitiesClassTitle>Common Stock</securitiesClassTitle>
      <acquiredDate>01/18/2025</acquiredDate>
      <natureOfAcquisitionTransaction>Vesting of restricted stock unit award</natureOfAcquisitionTransaction>
      <nameOfPersonfromWhomAcquired>Y-mAbs Therapeutics, Inc.</nameOfPersonfromWhomAcquired>
      <isGiftTransaction>N</isGiftTransaction>
      <amountOfSecuritiesAcquired>3817</amountOfSecuritiesAcquired>
      <paymentDate>01/18/2025</paymentDate>
      <natureOfPayment>Granted as part of issuer equity compensation plan</natureOfPayment>
    </securitiesToBeSold>
    <nothingToReportFlagOnSecuritiesSoldInPast3Months>Y</nothingToReportFlagOnSecuritiesSoldInPast3Months>
    <noticeSignature>
      <noticeDate>03/07/2025</noticeDate>
      <signature>Thomas Gad</signature>
    </noticeSignature>
  </formData>
</edgarSubmission>
